Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
837 participants
OBSERVATIONAL
2023-02-10
2032-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)
NCT01432509
Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk
NCT00520962
Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France - 3-year Follow-up
NCT06866002
Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France
NCT05717491
Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile
NCT02080741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The monitoring of the cohort will take place for at least 10 years with a follow-up of all participants every three years. To detect individuals who develop dysglycemia during the study, a glucose tolerance test (GTT) and HbA1c measurement will be conducted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T2D group
subjects with type 2 diabetes
Questionnaire
Follow-up questionnaire
Non-T2D group
healthy subjects
OGTT
Oral Glucose Tolerance Test
HbA1c
HbA1c measurement
Questionnaire
Follow-up questionnaire
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OGTT
Oral Glucose Tolerance Test
HbA1c
HbA1c measurement
Questionnaire
Follow-up questionnaire
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjets who sign informed consent to participate in the study
Exclusion Criteria
* Subjects refusing to participate
* Pregnant or breastfeeding
* Subjects in emergency situations, under legal protection or unable to provide informed -consent
* Subjects lost to follow-up or died
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur de Lille
OTHER
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guillaume CHARPENTIER, Dr
Role: PRINCIPAL_INVESTIGATOR
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Évry, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01538-35
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.